Neuroone Medical Technologies (NMTC) Cost of Revenue (2011 - 2026)

Neuroone Medical Technologies (NMTC) has reported Cost of Revenue for 8 consecutive years, with $790496.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 1.19% year-over-year to $790496.0; the trailing twelve-month figure through Jun 2026 stood at $4.2 million (up 46.06% YoY), and the FY2025 full-year result was $4.0 million, up 66.7% from the prior year.
• Cost of Revenue eased to $790496.0 in Q2 2026 per NMTC's latest filing, from $871786.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $1.3 million in Q4 2024 and bottomed at $38462.0 in Q2 2022.
• Historically, Cost of Revenue has averaged $611541.9 across 5 years, with a median of $581807.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue jumped 904.21% in 2023, then plunged 76.06% in 2024.
• Over 5 years, Cost of Revenue stood at $126886.0 in 2022, then surged by 460.61% to $711335.0 in 2023, then surged by 89.4% to $1.3 million in 2024, then fell by 1.67% to $1.3 million in 2025, then sank by 40.33% to $790496.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $790496.0, $871786.0, and $1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.